Literature DB >> 17215632

Clues to cardiovascular risk: an office-based approach.

Andrew P DeFilippis1, Joshua M Larned, Jason H Cole, Christine Nell-Dybdahl, Joseph I Miller, Laurence S Sperling.   

Abstract

Current tools for predicting coronary heart disease risk in the asymptomatic patient fall into 2 major categories: traditional population-based models and noninvasive imaging techniques. Population-based models that estimate cardiovascular risk are powerful clinical tools but do not utilize a large volume of patient-specific data that are readily available to the clinician and may help to identify at-risk patients. The use of high-technology noninvasive imaging has not been consistently validated and clinicians or patients often lack the resources for such testing. This paper reviews several commonly encountered historical, physical, radiologic, laboratory, and electrocardiographic markers of increased cardiovascular risk that may enhance clinicians' ability to identify individual patients at increased risk for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215632     DOI: 10.1111/j.1520-037x.2007.05544.x

Source DB:  PubMed          Journal:  Prev Cardiol        ISSN: 1520-037X


  2 in total

1.  GAREM1 regulates the PR interval on electrocardiograms.

Authors:  Hye Ok Kim; Ji Eun Lim; Myung Jun Kim; Ji-One Kang; Sung-Moon Kim; Jeong Min Nam; Jihoon Tak; Hiroaki Konishi; Tasuku Nishino; In Song Koh; Young-Ho Jin; Hyung Hwan Baik; Jin-Bae Kim; Mi Kyung Kim; Bo Youl Choi; Sang-Hak Lee; Yangsoo Jang; Jinho Shin; Bermseok Oh
Journal:  J Hum Genet       Date:  2017-12-22       Impact factor: 3.172

2.  Heritabilities, proportions of heritabilities explained by GWAS findings, and implications of cross-phenotype effects on PR interval.

Authors:  Claudia Tamar Silva; Jan A Kors; Najaf Amin; Abbas Dehghan; Jacqueline C M Witteman; Rob Willemsen; Ben A Oostra; Cornelia M van Duijn; Aaron Isaacs
Journal:  Hum Genet       Date:  2015-09-18       Impact factor: 5.881

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.